Long-Term Efficacy of Postpartum Intravenous Iron Therapy by Becuzzi, Nadine
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
Long-Term Efficacy of Postpartum Intravenous Iron Therapy
Becuzzi, Nadine
Abstract: Unspecified
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-116446
Published Version
Originally published at:
Becuzzi, Nadine. Long-Term Efficacy of Postpartum Intravenous Iron Therapy. 2015, University of
Zurich, Faculty of Medicine.
UniversitätsSpital  Zürich  
Klinik  für  Geburtshilfe  
Direktor:  Prof.  Dr.  med.  R.  Zimmermann  
  
  
  
  
  
  
  
  
Arbeit  unter  Leitung  von  PD  Dr.  med.  A.  Krafft  
  
  
  
  
  
  
  
  
Long-­Term  Efficacy  of  Postpartum  Intravenous  Iron  Therapy  
  
  
  
  
  
  
  
  
INAUGURAL-­DISSERTATION  
zur  Erlangung  der  Doktorwürde  der  Medizinischen  Fakultät  
der  Universität  Zürich  
  
  
  
  
  
  
  
  
vorgelegt  von  
Nadine  Stefania  Becuzzi  
  
  
  
  
  
  
  
  
Genehmigt  auf  Antrag  von  Prof.  Dr.  med.  R.  Zimmermann  
Zürich  2015     
Publikationshinweis  
  
Long-­Term  Efficacy  of  Postpartum  Intravenous  Iron  Therapy  
  
  
Publiziert  am:     06.  November  2014  
  
Journal:           BioMed  Research  International  Hematology,  Volume  2014  (2014),  
         Article  ID  815437,  5  pages  
         http://www.hindawi.com/journals/bmri/2014/815437/  
       
Publikation  
  
BioMed  Research  International  
Volume  2014  (2014),  Article  ID  815437,  5  pages  
http://dx.doi.org/10.1155/2014/815437  
Clinical  Study  
     
Long-­Term  Efficacy  of  Postpartum  Intravenous  Iron  Therapy  
Nadine  Becuzzi,  Roland  Zimmermann,  and  Alexander  Krafft  
Division  of  Obstetrics,  Department  of  Obstetrics  and  Gynecology,  University  Hospital  Zurich,  8091  
Zurich,  Switzerland  
Received  10  June  2014;;  Accepted  7  September  2014;;  Published  6  November  2014  
Academic  Editor:  Pedro  Cabrales  
  
Copyright  ©  2014  Nadine  Becuzzi  et  al.  This  is  an  open  access  article  distributed  under  the  Creative  
Commons  Attribution   License,  which   permits   unrestricted   use,   distribution,   and   reproduction   in   any  
medium,  provided  the  original  work  is  properly  cited.  
     
  
 2 BioMed Research International
Table 1: Baseline data and characteristics.
Characteristics Oral iron Intravenous + oral iron 푃
(푁 = 150) (푁 = 75)
Maternal age at delivery (years) 32.1 (5.4) 31.5 (6.1) 0.46
Gestational age (weeks) 39.2 (2.9) 39.1 (3.0) 0.91
Gravidity 2.0 (1.4) 2.1 (1.6) 0.77
Parity 1.6 (0.9) 1.5 (1.1) 0.63
Blood loss, estimated (mL) 537.2 (283.5) 625.9 (404.9) 0.06
Hb after delivery (g/dL) 10.1 (0.3) [9.5–10.5] 9.1 (0.3) [8.5–9.5] <0.0001
Haematocrit after delivery (%) 29.5 (1.4) [25.4–36.2] 26.9 (1.7) [23–31.5] <0.0001
Mode of delivery
Vaginal spontaneous 54 (36%) 33 (44%)
Vaginal operative 28 (18.7%) 9 (12%)
Caesarean section 68 (45.3%) 33 (44%)
Values are expressed as mean (SD) [range], or numbers and percentages.
discharge for those with Hb 9.6–10.5 g/dL measured 24–48 h
post-partum (푛 = 150) or in the case of post-partum Hb
8.5–9.5 g/dL (푛 = 77) they had received a single infusion
of 500mg iron carboxymaltose (Ferinject) diluted in 100mL
sodium chloride 0.9% followed by the same prescription for
oral iron sulphate containing 80mg elemental iron/day.
Patients were questioned 6 months postpartum about
oral medication compliance, physical performance (con-
ventional Hayes and Paterson visual analogue scale (VAS)
from 1 to 10 comparable to a VAS for pain), diet (veg-
etarian/nonvegetarian), duration of breast-feeding, degree
of menstrual blood loss, and adverse events during intra-
venous and oral iron therapy. Exclusion criteria were surgery,
blood transfusion, and/or additional intravenous iron ther-
apy within the intervening 6months.
2.1. Statistical Analysis. Groups were compared using the
Mann-Whitney test or Pearson’s chi-squared test where
appropriate. A 푃 value < 0.05 was used in all tests. Data are
given as the mean ± SD. Sample sizes were calculated by
power analysis (StatView 5.0.1, SAS Institute, Cary,NC,USA).
3. Results
3.1. Patient Characteristics. After reviewing the records of
1509 women with postpartum anaemia over a 26-month
period, we included 225 women in the study. Three women
were administered an additional dose of intravenous iron
postpartum and were therefore excluded. None underwent
surgery or received blood transfusions in the 6 months
postpartum. The remaining 1281 women either could not be
reached or decided not to participate. One hundred and fifty
women had postpartum Hb 9.6–10.5 g/dL and were assigned
to oral iron only; 75 women had postpartum Hb 8.5–9.5 g/dL
and received intravenous + oral iron.Maternal age at delivery,
gestational age at delivery, number of previous pregnancies,
and number of previous births did not differ significantly
between the two groups (Table 1).
3.2. Haematological Response (Table 2). At 6 months only
three and four women remained anaemic in the oral and
intravenous + oral groups. Mean Hb increased from 10.1 g/dL
postpartum to 13.3 ± 0.83 g/dL at 6 months versus from
9.1 g/dL to 13.3 ± 0.84 g/dL (푃 = 0.68). Of all the other haema-
tological parameters, only mean corpuscular haemoglobin
significantly differed statistically between the groups, being
higher in the intravenous + oral group (푃 < 0.05).
3.3. Iron Status and Inflammatory Response. Mean ferritin
at 6 months was statistically significantly lower in the oral
group: 32.9 ± 20.1휇g/L (range 4–111 휇g/L) versus 57.7 ±
49.3 휇g/L (range 9–296휇g/L) (푃 < 0.0001).
CRP levels were similar in both groups: 2.0 ± 4.4mg/L
versus 1.8 ± 2.7mg/L.
3.4. Questionnaire Results (Table 3). Self-reported durations
of oral iron supplementation ranged from 0 to 180 days across
groups, with a median of 46 days in the intravenous + oral
group and 30 days in the oral iron group, respectively; 52% of
patients in intravenous + oral group and 20% of patients in
the oral iron group took no oral treatment at all.
Therewere no statistical significant intergroup differences
in breast-feeding practice and duration, proportion of vege-
tarians, self-rated physical performance, or reported return of
menstruation at 6 months (71.6% in the oral iron group and
62.7% in the intravenous + oral group).
3.5. Adverse Events. No intravenous iron recipient could
recall any adverse effects, although one woman elected
not to participate due to persistent cutaneous infiltration
after injection-related extravasation. While the intravenous
administration was generally very well tolerated, the women
in the orally supplemented group frequently complained of
gastrointestinal symptoms, such as abdominal pain and
constipation.
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Table 2: Laboratory data 6months post-partum.
Characteristics Oral iron Intravenous + oral iron 푃
(푁 = 150) (푁 = 75)
Hb (g/dL) 13.3 (0.8) [10.9–15.3] 13.3 (0.8) [11.1–15.7] 0.68
Haematocrit (%) 39.5 (2.3) [32.8–46.4] 39.4 (2.6) [34.1–47.6] 0.78
MCV (fL) 85.6 (4.4) [71.7–97.8] 86.6 (5.1) [72.7–97.7] 0.13
MCH (pg) 28.8 (1.7) [22.5–32.1] 29.3 (1.9) [21.8–34] 0.047
MCHC (g/dL) 33.6 (1.0) [30.4–35.9] 33.8 (1.1) [30.0–37.3] 0.15
Microcytes (%) 1.5 (1.9) [0.1–13.2] 1.3 (2.1) [0.1–13.9] 0.48
Hypochromic erythrocytes (%) 1.7 (3.6) [0.1–24.9] 1.3 (3.0) [0.1–18.9] 0.43
Ferritin (휇g/L) 32.9 (20.1) [4–111] 57.7 (49.3) [9–296] <0.0001
CRP (mg/L) 2.0 (4.4) [0–39] 1.8 (2.7) [0–11] 0.69
Values are expressed as mean (SD) [range].
Table 3: Questionnaire data at 6months post-partum.
Oral iron Intravenous + oral iron 푃
(푁 = 150) (푁 = 75)
Median duration of 80mg/d oral iron sulphate
supplementation (days) (all patients) 30 (46.8) [0–180] 46 (45.2) [0–180] .02
Women taking oral iron supplementation [푁 (%)] 120 (80%) 36 (48%) .006
Breast-feeding women [푁 (%)] 131 (87.3%)(mean 20.9 weeks) 68 (90.7%)(mean 20.7 weeks) .84
Vegetarians [푁 (%)] 11 (7.4%) 8 (10.8%) .34
Mean physical performance (scale 1–10) 6.9 (1.9) [2–10] 7.2 (1.7) [2–10] .36
Menstruation 6months post-partum
None 42 (28.4%) 28 (37.3%) .29
Yes 106 (71.6%) 47 (62.7%)
Values are expressed as mean (SD) [range], or numbers and percentages.
4. Discussion
Our results show that iron supplementation, whether oral
only or intravenous + oral, is an effective treatment of post-
partum anaemia. Women with initially more severe anaemia
treated with intravenous + oral iron reached the same Hb
level 6 months later as those prescribed oral iron for mild
anaemia. However, our data show that intravenous supple-
mentation is the more effective approach for long-term iron
store replenishment. Safety and tolerability studies of iron
carboxymaltose show infrequent side effects [14–16].
Previous studies found oral iron and intravenous iron
to be equieffective treatments for correcting postpartum
anaemic Hb levels up to the initial three months [9, 11].
The novelty of our study is that we measured laboratory
parameters at 6months, thus giving a more accurate estimate
of long-term effect.
Despite being anaemic after delivery, all but seven
patients (four and three, resp.) had normal Hb levels at 6
months.The lowestHb at 6monthswas 10.9 g/dL.One patient
in the intravenous + oral group with an Hb of 11.2 g/dL
combined with a ferritin of 296휇g/L was referred to a
haematologist for a possible haemoglobinopathy.
Mean ferritin levels were statistically significantly higher
in the intravenous + oral group: although these women had
been more anaemic on starting treatment, their iron stores
were better restored half a year later. One reason might be
the well-documented problems associated with the intestinal
absorption of oral iron, including iron sulphate. Various
factors such as diet may impair oral iron uptake. Postpartum
serum ferritin levels were notmeasured given that ferritin can
be elevated as an acute-phase protein for at least the first two
weeks of the puerperium, thus showing no correlation with
iron stores [17].
Gastrointestinal side effects are a well-recognised con-
tributor to poor patient compliance with long-term oral iron
treatment [18]. Many of the women in our study who ended
oral iron supplementation shortly after discharge complained
of abdominal pain and constipation. Twenty percent in the
oral iron alone group and 52% of women in the intravenous
+ oral group did not even start oral treatment. One might
speculate that the statistical significant higher rate of non-
starters of oral iron in intravenous + oral group is based on a
lesser psychological strain after having had an iron infusion.
However, the remaining women who continued oral treat-
ment must be presumed to have done so, based on their self-
reported declarations, for considerably longer than the pre-
scribed 6weeks (42 days) in order to have achieved a median
duration of oral iron supplementation of 46 days. The com-
pliance figures in these women were higher than expected,
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bearing in mind that they were not being regularly encour-
aged to take the tablets.
The fact that we administered the questionnaire retro-
spectively, 4.5 months after the nominal completion of the 6
week oral therapy, could account for inaccurate recollection.
We conclude from the apparent spread of self-reported
compliance data and the absence of any external compliance
monitoring that our data simply reflect the noninterventional
observational nature of our study. They are the findings to
be expected under real-life practice conditions, representing
actual outcomes in unobserved patients in contrast to data
obtained in studies of closely supervised patients.
Our findings are consistent with those of Bhandal and
Russell who showed that intravenous iron sucrose increases
Hb levels more rapidly and replenishes iron stores more
efficiently than oral iron sulphate [9]. On postpartum day 40
Hb levels in both their study groups were similar, but iron
reserves were significantly higher in the intravenous group.
Our study now shows that this difference remains statistically
significant for up to 6 months. However, in contrast to our
own population, the women in the Bhandal and Russell study
were all severely anaemic, with similarly low mean group Hb
levels on starting treatment (7.5 g/dL and 7.3 g/dL). We also
prescribed a lower dose of oral iron sulphate than Bhandal
and Russell in order to maintain tolerability while remaining
effective in restoring the depleted iron stores [19].
Given that postpartum injection of intravenous iron
carboxymaltose is more effective than oral alternatives in
replenishing iron resources, we would advocate its use as the
treatment of choice not only in moderately severe anaemia
but also in mild postpartum anaemia, in particular for
women planning a subsequent pregnancy. However, further
studies are needed to determine the precise impact of post-
partum anaemia therapy on a future pregnancy.
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